# Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

> **NCT00004067** · PHASE3 · COMPLETED · sponsor: **NSABP Foundation Inc** · enrollment: 2130 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** herceptin
- **DRUG:** adriamycin
- **DRUG:** cyclophosphamide
- **DRUG:** taxol

## Key facts

- **NCT ID:** NCT00004067
- **Lead sponsor:** NSABP Foundation Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** 2005-03
- **Final completion:** 2019-11
- **Target enrollment:** 2130 (ACTUAL)
- **Last updated:** 2021-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004067, "Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00004067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*